CNTA
Centessa Pharmaceuticals plc
Price Chart
Latest Quote
$40.02
+0.15 (+0.38%)
Current Price
| Previous Close | $39.87 |
| Open | $39.83 |
| Day High | $40.07 |
| Day Low | $39.78 |
| Volume | 5,551,156 |
Stock Information
| Shares Outstanding | 154.73M |
| Total Debt | $118.56M |
| Cash Equivalents | $276.59M |
| Net Income | $-250.64M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $6.19B |
| EPS (TTM) | $-1.78 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $5.99B |
| Income | $-250.64M |
| Book/sh | $3.15 |
| Cash/sh | $1.79 |
| Employees | 129 |
Financial Ratios
| Quick Ratio | 9.27 |
| Current Ratio | 9.53 |
| Debt/Eq | 24.33 |
Returns & Margins
| ROA | -27.43% |
| ROE | -57.38% |
Ownership
| Insider Ownership | 0.51% |
| Institutional Ownership | 96.98% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -22.37 |
| P/B | 12.70 |
Analyst Data
| Recommendation | buy |
| Target Price | $44.17 |
Technical Indicators
| SMA20 | $39.79 |
| SMA50 | $39.66 |
| SMA200 | $28.96 |
| RSI | 62.04 |
| ATR | 0.1825 |
| Shares Float | 92.48M |
| Short Float | 1.96% |
| Short Ratio | 2.18 |
| Volatility | 1.12 |
| Rel Volume | 3.41 |
Performance History
| Week | +0.63% |
| Month | +0.81% |
| Quarter | +41.21% |
| 6 Months | +55.60% |
| YTD | +68.93% |
| Year | +217.62% |
| 3 Years | +755.13% |
| 5 Years | +84.34% |
| 10 Years | +84.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $40.02 | 5,588,700 |
| 2026-06-17 | $39.87 | 2,943,900 |
| 2026-06-16 | $39.75 | 2,216,200 |
| 2026-06-15 | $39.76 | 1,612,500 |
| 2026-06-12 | $39.72 | 1,322,800 |
| 2026-06-11 | $39.77 | 871,100 |
| 2026-06-10 | $39.69 | 1,780,800 |
| 2026-06-09 | $39.76 | 2,302,700 |
| 2026-06-08 | $39.70 | 553,300 |
| 2026-06-05 | $39.62 | 1,702,200 |
| 2026-06-04 | $39.80 | 1,972,500 |
| 2026-06-03 | $39.85 | 840,800 |
| 2026-06-02 | $39.90 | 1,133,600 |
| 2026-06-01 | $39.86 | 1,458,400 |
| 2026-05-29 | $39.76 | 922,300 |
| 2026-05-28 | $39.81 | 776,400 |
| 2026-05-27 | $39.77 | 1,079,400 |
| 2026-05-26 | $39.78 | 1,209,400 |
| 2026-05-22 | $39.75 | 707,500 |
| 2026-05-21 | $39.81 | 1,745,100 |
| 2026-05-20 | $39.75 | 906,300 |
| 2026-05-19 | $39.70 | 787,600 |
About Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
đ° Latest News
Lilly Goes on $20 Billion Buying Spree as It Seeks Next Act
Bloomberg âĸ 2026-05-27T13:37:06Z
Here is Why Eli Lilly (LLY) is One of the Best Stocks to Buy for the Next 15 Years
Insider Monkey âĸ 2026-05-08T11:16:02Z
Update: Market Chatter: Eli Lilly Plans to Sell About $8 Billion of Bonds to Fund Acquisitions
MT Newswires âĸ 2026-05-06T15:35:16ZIs It Too Late To Consider Centessa Pharmaceuticals (CNTA) After A 191% One Year Surge?
Simply Wall St. âĸ 2026-05-03T19:12:26Z
Guggenheim Raises PT on Eli Lilly (LLY) Amid Several Acquisition Deals
Insider Monkey âĸ 2026-04-29T16:03:24Z
Is This $6.3 Billion Deal a Game Changer for Eli Lilly?
Motley Fool âĸ 2026-04-16T13:50:00Z
Here Are Mondayâs Top Wall Street Analyst Research Calls: Adobe, Best Buy, Bilibili, Constellation Brands, CoreWeave, Nike, Starbucks, T-Mobile, and More
24/7 Wall St. âĸ 2026-04-13T10:50:44Z
Looks Like M&A Week in 3 Different Sectors
Motley Fool âĸ 2026-04-08T16:22:12Z
Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines
Zacks âĸ 2026-04-06T19:06:00Z
Eli Lilly Obesity Pill Approval And Sleep Deal Reshape Growth Story
Simply Wall St. âĸ 2026-04-05T13:05:47Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $15,000,000 | $0 | $6,853,000 | $0 |
| Operating Revenue | $15,000,000 | $0 | $6,853,000 | $0 |
| Expenses | ||||
| Interest Expense | $11,459,000 | $10,090,000 | $9,906,000 | $7,277,000 |
| Total Expenses | $222,692,000 | $201,055,000 | $178,136,000 | $210,283,000 |
| Other Income Expense | $2,911,000 | $-35,784,000 | $-5,428,000 | $362,000 |
| Other Non Operating Income Expenses | $2,911,000 | $-1,687,000 | $-5,428,000 | $2,342,000 |
| Net Non Operating Interest Income Expense | $9,068,000 | $3,926,000 | $570,000 | $-7,033,000 |
| Interest Expense Non Operating | $11,459,000 | $10,090,000 | $9,906,000 | $7,277,000 |
| Operating Expense | $222,692,000 | $201,055,000 | $178,136,000 | $210,283,000 |
| General And Administrative Expense | $50,468,000 | $50,811,000 | $53,731,000 | $55,200,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-197,532,000 | $-235,757,000 | $-151,085,000 | $-216,207,000 |
| Net Interest Income | $9,068,000 | $3,926,000 | $570,000 | $-7,033,000 |
| Interest Income | $20,527,000 | $14,016,000 | $10,476,000 | $244,000 |
| Normalized Income | $-197,532,000 | $-210,184,250 | $-151,085,000 | $-214,233,817 |
| Net Income From Continuing And Discontinued Operation | $-197,532,000 | $-235,757,000 | $-151,085,000 | $-216,207,000 |
| Total Operating Income As Reported | $-207,692,000 | $-201,055,000 | $-171,283,000 | $-212,263,000 |
| Net Income Common Stockholders | $-197,532,000 | $-235,757,000 | $-151,085,000 | $-216,207,000 |
| Net Income | $-197,532,000 | $-235,757,000 | $-151,085,000 | $-216,207,000 |
| Net Income Including Noncontrolling Interests | $-197,532,000 | $-235,757,000 | $-151,085,000 | $-216,207,000 |
| Net Income Continuous Operations | $-197,532,000 | $-235,757,000 | $-151,085,000 | $-216,207,000 |
| Pretax Income | $-195,713,000 | $-232,913,000 | $-176,141,000 | $-216,954,000 |
| Special Income Charges | $0 | $-34,097,000 | $0 | $-1,980,000 |
| Interest Income Non Operating | $20,527,000 | $14,016,000 | $10,476,000 | $244,000 |
| Operating Income | $-207,692,000 | $-201,055,000 | $-171,283,000 | $-210,283,000 |
| Per Share | ||||
| Diluted EPS | $-1.46 | $-2.06 | $-1.57 | $-2.31 |
| Basic EPS | $-1.46 | $-2.06 | $-1.57 | $-2.31 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $-8,524,250 | $0 | $-6,817 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-183,333,000 | $-187,784,000 | $-165,425,000 | $-207,566,000 |
| Total Unusual Items | $0 | $-34,097,000 | $0 | $-1,980,000 |
| Total Unusual Items Excluding Goodwill | $0 | $-34,097,000 | $0 | $-1,980,000 |
| Reconciled Depreciation | $921,000 | $942,000 | $810,000 | $131,000 |
| EBITDA (Bullshit earnings) | $-183,333,000 | $-221,881,000 | $-165,425,000 | $-209,546,000 |
| EBIT | $-184,254,000 | $-222,823,000 | $-166,235,000 | $-209,677,000 |
| Diluted Average Shares | $135,715,608 | $114,473,449 | $96,177,578 | $93,400,513 |
| Basic Average Shares | $135,715,608 | $114,473,449 | $96,177,578 | $93,400,513 |
| Diluted NI Availto Com Stockholders | $-197,532,000 | $-235,757,000 | $-151,085,000 | $-216,207,000 |
| Tax Provision | $1,819,000 | $2,844,000 | $-25,056,000 | $-747,000 |
| Research And Development | $172,224,000 | $150,244,000 | $124,405,000 | $155,083,000 |
| Selling General And Administration | $50,468,000 | $50,811,000 | $53,731,000 | $55,200,000 |
| Other Gand A | $21,082,000 | $19,914,000 | $26,106,000 | $29,279,000 |
| Salaries And Wages | $29,386,000 | $30,897,000 | $27,625,000 | $25,921,000 |
| Other Special Charges | - | $34,097,000 | - | - |
| Restructuring And Mergern Acquisition | - | - | $0 | $1,980,000 |
Fetched: 2026-06-08
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $526,863,000 | $401,545,000 | $236,244,000 | $336,169,000 |
| Total Assets | $687,495,000 | $576,798,000 | $360,246,000 | $444,307,000 |
| Total Non Current Assets | $319,620,000 | $40,389,000 | $45,154,000 | $6,560,000 |
| Other Non Current Assets | $1,440,000 | $2,046,000 | $2,554,000 | $1,880,000 |
| Non Current Deferred Assets | $24,778,000 | $26,586,000 | $29,647,000 | $3,512,000 |
| Non Current Deferred Taxes Assets | $24,778,000 | $26,586,000 | $29,647,000 | $3,512,000 |
| Current Assets | $367,875,000 | $536,409,000 | $315,092,000 | $437,747,000 |
| Other Current Assets | $1,827,000 | $1,495,000 | $1,621,000 | $3,271,000 |
| Prepaid Assets | $11,127,000 | $7,154,000 | $17,774,000 | $14,109,000 |
| Receivables | $60,341,000 | $45,583,000 | $39,148,000 | $26,723,000 |
| Taxes Receivable | $56,981,000 | $45,296,000 | $39,148,000 | $26,723,000 |
| Accrued Interest Receivable | $3,360,000 | $287,000 | - | - |
| Cash Cash Equivalents And Short Term Investments | $294,580,000 | $482,177,000 | $256,549,000 | $393,644,000 |
| Cash And Cash Equivalents | $61,299,000 | $383,221,000 | $128,030,000 | $393,644,000 |
| Debt | ||||
| Net Debt | $48,796,000 | - | - | - |
| Total Debt | $118,381,000 | $117,828,000 | $84,588,000 | $69,800,000 |
| Long Term Debt And Capital Lease Obligation | $117,668,000 | $117,226,000 | $84,588,000 | $69,800,000 |
| Long Term Debt | $110,095,000 | $108,940,000 | $75,700,000 | $69,800,000 |
| Current Debt And Capital Lease Obligation | $713,000 | $602,000 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $160,632,000 | $175,253,000 | $124,002,000 | $108,138,000 |
| Total Non Current Liabilities Net Minority Interest | $117,697,000 | $117,255,000 | $84,617,000 | $69,800,000 |
| Other Non Current Liabilities | $29,000 | $29,000 | $29,000 | - |
| Current Liabilities | $42,935,000 | $57,998,000 | $39,385,000 | $38,338,000 |
| Other Current Liabilities | $217,000 | $108,000 | $839,000 | $690,000 |
| Payables And Accrued Expenses | $27,538,000 | $47,823,000 | $31,813,000 | $30,384,000 |
| Interest Payable | $840,000 | $0 | - | - |
| Payables | $7,582,000 | $7,978,000 | $11,927,000 | $15,418,000 |
| Total Tax Payable | $0 | $835,000 | $112,000 | $1,582,000 |
| Income Tax Payable | $0 | $835,000 | $112,000 | $1,582,000 |
| Accounts Payable | $7,582,000 | $7,143,000 | $11,815,000 | $13,836,000 |
| Derivative Product Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $526,863,000 | $401,545,000 | $236,244,000 | $336,169,000 |
| Total Equity Gross Minority Interest | $526,863,000 | $401,545,000 | $236,244,000 | $336,169,000 |
| Stockholders Equity | $526,863,000 | $401,545,000 | $236,244,000 | $336,169,000 |
| Gains Losses Not Affecting Retained Earnings | $2,714,000 | $4,213,000 | $1,493,000 | $-1,497,000 |
| Other Equity Adjustments | $2,714,000 | $4,213,000 | $1,493,000 | $-1,497,000 |
| Retained Earnings | $-1,186,234,000 | $-988,702,000 | $-752,945,000 | $-601,860,000 |
| Preferred Securities Outside Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $149,228,068 | $132,631,587 | $98,774,827 | $94,843,391 |
| Share Issued | $149,228,068 | $132,631,587 | $98,774,827 | $94,843,391 |
| Tangible Book Value | $526,863,000 | $401,545,000 | $236,244,000 | $336,169,000 |
| Invested Capital | $636,958,000 | $510,485,000 | $311,944,000 | $405,969,000 |
| Working Capital | $324,940,000 | $478,411,000 | $275,707,000 | $399,409,000 |
| Capital Lease Obligations | $8,286,000 | $8,888,000 | $8,888,000 | $0 |
| Total Capitalization | $636,958,000 | $510,485,000 | $311,944,000 | $405,969,000 |
| Additional Paid In Capital | $1,709,978,000 | $1,385,675,000 | $987,423,000 | $939,261,000 |
| Capital Stock | $405,000 | $359,000 | $273,000 | $265,000 |
| Common Stock | $405,000 | $359,000 | $273,000 | $265,000 |
| Long Term Capital Lease Obligation | $7,573,000 | $8,286,000 | $8,888,000 | $0 |
| Current Capital Lease Obligation | $713,000 | $602,000 | - | - |
| Pensionand Other Post Retirement Benefit Plans Current | $14,467,000 | $9,465,000 | $6,733,000 | $7,264,000 |
| Current Accrued Expenses | $19,956,000 | $39,845,000 | $19,886,000 | $14,966,000 |
| Investments And Advances | $282,548,000 | $0 | - | - |
| Net PPE | $10,854,000 | $11,757,000 | $12,953,000 | $1,168,000 |
| Accumulated Depreciation | $-1,099,000 | $-791,000 | $-462,000 | $-164,000 |
| Gross PPE | $11,953,000 | $12,548,000 | $13,415,000 | $1,332,000 |
| Machinery Furniture Equipment | $1,906,000 | $1,535,000 | $1,501,000 | $442,000 |
| Buildings And Improvements | $10,047,000 | $11,013,000 | $11,914,000 | - |
| Properties | $0 | $0 | $0 | - |
| Other Short Term Investments | $233,281,000 | $98,956,000 | $128,519,000 | $0 |
| Construction In Progress | - | - | $0 | $890,000 |
| Preferred Stock | - | - | - | - |
| Line Of Credit | - | - | - | - |
Fetched: 2026-06-08
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-194,188,000 | $-142,089,000 | $-160,511,000 | $-201,683,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-193,817,000 | $-142,055,000 | $-160,342,000 | $-200,546,000 |
| Cash Flow From Continuing Operating Activities | $-193,817,000 | $-142,055,000 | $-160,342,000 | $-200,546,000 |
| Operating Gains Losses | - | $34,097,000 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-371,000 | $-34,000 | $-169,000 | $-1,137,000 |
| Investing Cash Flow | $-418,531,000 | $31,267,000 | $-127,004,000 | $-931,000 |
| Cash Flow From Continuing Investing Activities | $-418,531,000 | $31,267,000 | $-127,004,000 | $-931,000 |
| Net Other Investing Changes | - | - | - | $206,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $275,358,000 | $359,605,000 | $20,807,000 | $0 |
| Financing Cash Flow | $291,528,000 | $364,752,000 | $21,117,000 | $457,000 |
| Cash Flow From Continuing Financing Activities | $291,528,000 | $364,752,000 | $21,117,000 | $457,000 |
| Net Other Financing Charges | $-5,192,000 | $-5,318,000 | - | $-261,000 |
| Net Common Stock Issuance | $275,358,000 | $359,605,000 | $20,807,000 | $0 |
| Common Stock Issuance | $275,358,000 | $359,605,000 | $20,807,000 | $0 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $0 | $-110,097,000 | $0 | - |
| Issuance Of Debt | $0 | $109,335,000 | $0 | $0 |
| Interest Paid Supplemental Data | $9,464,000 | $10,085,000 | $9,906,000 | $7,277,000 |
| Income Tax Paid Supplemental Data | $1,331,000 | $82,000 | $2,943,000 | $1,299,000 |
| End Cash Position | $61,953,000 | $383,221,000 | $128,030,000 | $393,644,000 |
| Beginning Cash Position | $383,221,000 | $128,030,000 | $393,644,000 | $595,082,000 |
| Effect Of Exchange Rate Changes | $-448,000 | $1,227,000 | $615,000 | $-418,000 |
| Changes In Cash | $-320,820,000 | $253,964,000 | $-266,229,000 | $-201,020,000 |
| Proceeds From Stock Option Exercised | $21,362,000 | $11,227,000 | $310,000 | $718,000 |
| Net Issuance Payments Of Debt | $0 | $-762,000 | $0 | $0 |
| Net Long Term Debt Issuance | $0 | $-762,000 | $0 | $0 |
| Long Term Debt Payments | $0 | $-110,097,000 | $0 | - |
| Long Term Debt Issuance | $0 | $109,335,000 | $0 | $0 |
| Net Investment Purchase And Sale | $-418,160,000 | $31,301,000 | $-126,835,000 | $0 |
| Sale Of Investment | $321,601,000 | $171,834,000 | $138,075,000 | $0 |
| Purchase Of Investment | $-739,761,000 | $-140,533,000 | $-264,910,000 | $0 |
| Net PPE Purchase And Sale | $-371,000 | $-34,000 | $-169,000 | $-1,137,000 |
| Purchase Of PPE | $-371,000 | $-34,000 | $-169,000 | $-1,137,000 |
| Change In Working Capital | $-30,022,000 | $22,102,000 | $-18,858,000 | $-2,831,000 |
| Change In Other Current Assets | $253,000 | $298,000 | $-1,883,000 | $0 |
| Change In Payables And Accrued Expense | $-15,166,000 | $18,186,000 | $-3,519,000 | $12,612,000 |
| Change In Accrued Expense | $-15,216,000 | $22,771,000 | $-797,000 | $6,261,000 |
| Change In Payable | $50,000 | $-4,585,000 | $-2,722,000 | $6,351,000 |
| Change In Account Payable | $50,000 | $-4,585,000 | $-2,722,000 | $6,351,000 |
| Change In Prepaid Assets | $-7,852,000 | $10,219,000 | $-1,364,000 | $-3,732,000 |
| Change In Receivables | $-7,257,000 | $-6,601,000 | $-12,092,000 | $-11,711,000 |
| Other Non Cash Items | $1,147,000 | $62,000 | $28,000 | $173,000 |
| Stock Based Compensation | $30,962,000 | $33,546,000 | $29,392,000 | $24,965,000 |
| Unrealized Gain Loss On Investment Securities | $0 | $300,000 | $5,900,000 | $-3,920,000 |
| Amortization Of Securities | $-1,802,000 | $0 | - | - |
| Deferred Tax | $2,509,000 | $2,653,000 | $-26,529,000 | $-2,857,000 |
| Deferred Income Tax | $2,509,000 | $2,653,000 | $-26,529,000 | $-2,857,000 |
| Depreciation Amortization Depletion | $921,000 | $942,000 | $810,000 | $131,000 |
| Depreciation And Amortization | $921,000 | $942,000 | $810,000 | $131,000 |
| Net Income From Continuing Operations | $-197,532,000 | $-235,757,000 | $-151,085,000 | $-216,207,000 |
| Net Business Purchase And Sale | - | - | - | $0 |
| Sale Of Business | - | - | - | $0 |
Fetched: 2026-06-08